Filtered By:
Source: American Heart Journal
Condition: Bleeding
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 167 results found since Jan 2013.
Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial
Publication date: September 2016 Source:American Heart Journal, Volume 179 Author(s): Michael D. Ezekowitz, Charles V. Pollack, Paul Sanders, Jonathan L. Halperin, Judith Spahr, Nilo Cater, William Petkun, Andrei Breazna, Paulus Kirchhof, Jonas Oldgren Stroke prevention in anticoagulation-naïve patients with atrial fibrillation undergoing cardioversion has not been systematically studied. Objective To determine outcomes in anticoagulation-naïve patients (defined as those receiving an anticoagulant for <48 hours during the index episode of atrial fibrillation) scheduled for cardioversion. Methods This...
Source: American Heart Journal - July 5, 2016 Category: Cardiology Source Type: research
Growth-Differentiation Factor 15 and Risk of Major Bleeding in Atrial Fibrillation: Insights from the RE-LY Trial
Conclusions In patients with AF, GDF-15 is an independent risk indicator for major bleeding and all-cause mortality, but not for stroke. Therefore, GDF-15 seems useful as a specific marker of bleeding in patients with AF on oral anticoagulant treatment.
Source: American Heart Journal - June 8, 2017 Category: Cardiology Source Type: research
Is There A Role For Pharmacokinetic/Pharmacodynamic Guided Dosing For Novel Oral Anticoagulants?
Publication date: Available online 10 October 2017 Source:American Heart Journal Author(s): Noel Chan, Philip T. Sager, Jack Lawrence, Thomas's Ortel, Paul Reilly, Scott Berkowitz, Dagmar Kubitza, John Eikelboom, Jeffry Florian, Norman Stockbridge, Martin Rose, Robert Temple, Jonathan H. Seltzer The novel direct oral anticoagulants (NOACs) represent a major advance in oral anticoagulant therapy, and are replacing vitamin K antagonists as the preferred options for many indications. Given in fixed doses without routine laboratory monitoring, they have been shown to be at least as effective in reducing thromboembolic stroke ...
Source: American Heart Journal - October 10, 2017 Category: Cardiology Source Type: research
Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?
Publication date: May 2018 Source:American Heart Journal, Volume 199 Author(s): Noel Chan, Philip T. Sager, Jack Lawrence, Thomas's Ortel, Paul Reilly, Scott Berkowitz, Dagmar Kubitza, John Eikelboom, Jeffry Florian, Norman Stockbridge, Martin Rose, Robert Temple, Jonathan H. Seltzer The novel direct oral anticoagulants (NOACs) represent a major advance in oral anticoagulant therapy and are replacing vitamin K antagonists as the preferred options for many indications. Given in fixed doses without routine laboratory monitoring, they have been shown to be at least as effective in reducing thromboembolic stroke as dose-adjus...
Source: American Heart Journal - February 23, 2018 Category: Cardiology Source Type: research
Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design
Publication date: Available online 7 March 2018 Source:American Heart Journal Author(s): Douglas L. Packer, Daniel B. Mark, Richard A Robb, Kristi Monahan, Tristram Bahnson, Kathleen Moretz, Jeanne Poole, Alice Mascette, Yves Rosenberg, Neal Jeffries, Hussein R. Al-Khalidi, Kerry L. Lee The Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA, NCT00911508)(1) trial is testing the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) is superior to current state-of-the-art pharmacologic therapy. This inte...
Source: American Heart Journal - March 8, 2018 Category: Cardiology Source Type: research
Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT registry®
ConclusionsIn the U.S. the majority of patients were discharged on DAPT following TAVR. Practice patterns varied significantly among hospitals. Patients discharged with DAPT had a similar adjusted risk of mortality, stroke and MI compared to antiplatelet monotherapy, though risk for bleeding was significantly higher. Future investigation is needed to define the optimal antiplatelet therapy for patients undergoing TAVR.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research
Association of Frailty and Cognitive Impairment with benefits of Oral anticoagulation in patients with atrial fibrillation
ConclusionThose with cognitive impairment or frailty in AF had higher predicted risk for stroke and higher observed mortality, yet were less likely to be treated with OAC. Despite this, the benefits of OAC were similar in patients with and without cognitive impairment or frailty.
Source: American Heart Journal - January 30, 2019 Category: Cardiology Source Type: research
Rationale and design of the Steroids in Cardiac Surgery trial
Conclusions: SIRS will lead to a better understanding of the safety and efficacy of prophylactic steroids for cardiac surgery requiring CBP.
Source: American Heart Journal - March 3, 2014 Category: Cardiology Authors: Richard Whitlock, Kevin Teoh, Jessica Vincent, P.J. Devereaux, Andre Lamy, Domenico Paparella, Yunxia Zuo, Daniel I. Sessler, Pallav Shah, Juan-Carlos Villar, Ganesan Karthikeyan, Gerard Urrútia, Alvaro Alvezum, Xiaohe Zhang, Seyed Hesameddin Abbasi, Hon Tags: Trial Design Source Type: research
Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Conclusions We observed no interaction between vorapaxar and clopidogrel after non–ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism.
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research
Patients’ Time in Therapeutic Range on Warfarin Among U.S. Atrial Fibrillation Patients: Results from ORBIT-AF Registry
Conclusions Among AF patients in US clinical practices, TTR on warfarin is suboptimal and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research
Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry
Conclusions Among patients with AF in US clinical practices, TTR on warfarin is suboptimal, and those at highest predicted risks for stroke and bleeding were least likely to be in therapeutic range.
Source: American Heart Journal - April 23, 2015 Category: Cardiology Source Type: research
Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: from the ACCOAST study
Conclusions In ACCOAST, early (<2.98 days) surgical revascularization carried increased risk of bleeding and ischemic complications without affecting all-cause mortality through 30 days. Baseline troponin and prasugrel pretreatment did not impact ischemic clinical outcomes.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
Publication date: Available online 18 January 2016 Source:American Heart Journal Author(s): Thomas J. Povsic, Matthew T. Roe, E. Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, C. Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown ...
Source: American Heart Journal - January 19, 2016 Category: Cardiology Source Type: research
Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial
Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research
